What buyers look for in a multi-site marketing function
The marketing due diligence questions that buyers ask in a multi-site healthcare transaction are consistent and predictable, regardless of specialty or platform size. Can the CMO demonstrate a clear, attributable connection between marketing spend and revenue outcomes? Is patient acquisition cost improving as the platform scales, or deteriorating? Is the marketing function documented and systematized, or is it dependent on specific people who may not survive the transition? Does the organic growth story hold up under quantitative scrutiny, or does it fall apart when buyers start asking for the underlying data? Platforms that can answer these questions with evidence are positioned for a premium. Those that cannot are subject to valuation adjustments, and the adjustments are rarely small.
Three marketing capabilities that add demonstrable value to a platform sale
Attribution infrastructure that connects media spend to production outcomes is the foundation. A DSO with over 150 locations rebuilt their attribution layer across 161 locations specifically because buyers in a prior process had questioned the integrity of their patient acquisition numbers. When attribution is documented and auditable, the organic growth story becomes defensible, not just asserted. Documented CAC improvement over time sends a different signal: it tells buyers the marketing engine gets more efficient as the platform scales, which is a direct argument for post-acquisition performance. And same-site revenue growth attributable to marketing, not to acquisitions, not to market tailwinds, is the quality-of-earnings argument that commands a multiple premium. Each of these capabilities takes time to build. None of them can be manufactured in the months before a transaction closes.
The organic growth premium
Organic growth is valued differently from acquisition-driven growth in multi-site healthcare transactions. Acquisition-driven growth requires continued capital deployment at the same or higher cost to maintain. Organic growth, same-site revenue improvement driven by patient reactivation, service mix optimization, and always-on local market campaigns, is scalable and does not require per-acquisition capital costs. When buyers evaluate a platform where organic growth is predictable, attributable, and driven by a documented marketing system, they apply a higher multiple to the EBITDA because the growth quality is demonstrably superior.
The marketing story in the investment memorandum
The investment memorandum that accompanies a recap or platform sale has to tell the marketing story in financial terms, and sophisticated buyers have gotten much better at reading it. They want to see patient acquisition cost trends across three to five years, not just a current CAC number. They want the same-site revenue growth that can be isolated from acquisition activity and attributed to specific marketing initiatives. They want De Novo ramp data measured against the original investment thesis, not just a general claim that new locations are performing. And they want the attribution infrastructure that makes all of those numbers auditable rather than constructed. When that evidence base exists, the marketing section of the investment memorandum becomes a value argument. When it does not, it becomes a liability.
Timeline to exit-ready
Building the marketing infrastructure that survives due diligence scrutiny typically requires 18 to 24 months of consistent investment and execution. Attribution infrastructure takes time to build and validate. CAC trends take time to establish. Same-site growth contribution takes multiple quarters to document compellingly. CMOs who begin building toward exit readiness only when the transaction timeline becomes clear are often too late to build the evidence base that commands a premium. The time to build exit-ready marketing infrastructure is at the beginning of the hold period, not at the end.
What Agency Creative means by exit-ready marketing
Agency Creative defines exit-ready marketing as a marketing function that can demonstrate, with documented financial data, that it is a repeatable, scalable system for generating organic growth, not a collection of individual campaigns that cannot be replicated by a new team or new ownership. Exit-ready marketing has attribution infrastructure, documented processes, performance trend data, and a reporting framework that survives the transition from one ownership group to the next. We help multi-site healthcare CMOs build toward this standard throughout the hold period so that when the transaction comes, the marketing story is already written.
“Buyers don’t take your marketing story at face value. They stress-test it. The platforms that command a premium are the ones where the data holds up under that pressure because someone built the infrastructure to make it holdable.”
Agency Creative helps multi-site healthcare CMOs build the marketing infrastructure that makes the exit-ready standard achievable. Let’s talk about what that looks like for your platform and timeline.
Learn how Agency Creative can help boost your brand by calling us at 972.488.1660 or by contacting us online.
See More Work
